[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001545:Benserazide / Q000008:administration & dosage / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000378:metabolism*; D007700:Kinetics; D007980:Levodopa / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D013997:Time Factors
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D007980:Levodopa; D001545:Benserazide